DAPAGLIFLOZIN
It is a drug of the gliflozin class, that inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium-glucose transport protein 2 (SGLT2).Type 2 diabetes mellitus.
Oral; 5-10mg every morning with or without food.
Hypersensitivity, end stage renal disease, patient on dialysis.
Paediatric: Safety and efficacy below 18 years not yet established. Pregnancy: Category C. Lactation: Not known if it is excreted in milk, decision to discontinue drug may be taken depending on importance of drug to mother. Elderly: In persons aged more than 75 years more side effects are seen related to kidney impairement.
Hypotension, Ketoacidosis, Acute Kidney Injury and Impairment in Renal Function, Urosepsis and Pyelonephritis, Hypoglycemia with Concomitant Use with Insulin and Insulin Secretagogues, Genital Mycotic Infections, Increases in Low-Density Lipoprotein Cholesterol, Bladder Cancer.
It will lead to positive urine glucose tests, urine glucose monitoring should not be done.
